The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citation
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
Items 1,101–1,158 of 1,158
Quantitative proteomics of synaptosome S‐nitrosylation in Alzheimer’s disease
Wijasa, T. S., Sylvester, M., Brocke‐Ahmadinejad, N., Schwartz, S., Santarelli, F., Gieselmann, V., Klockgether, T., Brosseron, F., & Heneka, M. T. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14870 · Cited by 41
Amyloid‐β induces sleep fragmentation that is rescued by fatty acid binding proteins in Drosophila
Gerstner, J. R., Lenz, O., Vanderheyden, W. M., Chan, M. T., Pfeiffenberger, C., & Pack, A. I. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23778 · Cited by 40
Hobel, Z., ageing, F. T. A. D. N. I. A. T. A. I. B. A. L. F. S. O., Isenberg, A. L., Raghupathy, D., Mack, W., & Pa, J. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180859 · Cited by 40
Martínez de Toda, I., Miguélez, L., Vida, C., Carro, E., & De la Fuente, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190198 · Cited by 40
Badea, A., Kane, L., Anderson, R. J., Qi, Y., Foster, M., Cofer, G. P., Medvitz, N., Buckley, A. F., Badea, A. K., Wetsel, W. C., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.08.014 · Cited by 39
Pettigrew, C., Soldan, A., Moghekar, A., Wang, M.-C., Gross, A. L., O’Brien, R., & Albert, M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.09.024 · Cited by 38
Aguilar, C., Muehlboeck, J.-S., Mecocci, P., Vellas, B., Tsolaki, M., Kloszewska, I., Soininen, H., Lovestone, S., Wahlund, L.-O., Simmons, A., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00145 · Cited by 34
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
Self-citationChouinard, A.-M., Larouche, E., Audet, M.-C., Hudon, C., & Goulet, S. (2019) · Aging & Mental Health · doi:10.1080/13607863.2018.1484890 · Cited by 35
Hurtado, M. O., Kohler, I., & de Lange, E. C. M. (2018) · Bioanalysis · doi:10.4155/bio-2018-0135 · Cited by 34
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34
Teixeira, A. L., Rocha, N. P., & Gatchel, J. (2023) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0043-1777774 · Cited by 33
Baba, Y., Inagaki, S., Nakagawa, S., Kobayashi, M., Kaneko, T., & Takihara, T. (2021) · Nutrients · doi:10.3390/nu13051700 · Cited by 33
Dang, C., Harrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Yassi, N., Hickey, M., Rainey-Smith, S., Robertson, J., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180507 · Cited by 31
Self-citationLiquid-liquid phase separation in Alzheimer’s disease
Fu, Q., Zhang, B., Chen, X., & Chu, L. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02407-3 · Cited by 33
Ibnidris, A., Robinson, J. N., Stubbs, M., Piumatti, G., Govia, I., & Albanese, E. (2022) · Systematic Reviews · doi:10.1186/s13643-022-02018-y · Cited by 30
Ding, Z., Leung, P.-Y., Lee, T.-L., & Chan, A. S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101886 · Cited by 31
Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease
Higginbotham, L., Dammer, E., Duong, D., Modeste, E., Montine, T., Lah, J., Levey, A., & Seyfried, N. (2019) · Proteomes · doi:10.3390/proteomes7030030 · Cited by 32
Self-citationAzarpazhooh, M. R., Avan, A., Cipriano, L. E., Munoz, D. G., Erfanian, M., Amiri, A., Stranges, S., & Hachinski, V. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101002 · Cited by 32
A genetics-based biomarker risk algorithm for predicting risk of Alzheimer's disease
Lutz, M. W., Sundseth, S. S., Burns, D. K., Saunders, A. M., Hayden, K. M., Burke, J. R., Welsh‐Bohmer, K. A., Roses, A. D., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.12.002 · Cited by 30
Leuzy, A., Zimmer, E. R., Heurling, K., Rosa-Neto, P., & Gauthier, S. (2014) · Amyloid · doi:10.3109/13506129.2014.926267 · Cited by 31
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Self-citationAssociation between thyroid function and Alzheimer's disease: A systematic review
Figueroa, P. B. S., Ferreira, A. F. F., Britto, L. R., Doussoulin, A. P., & Torrão, A. D. S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00760-1 · Cited by 28
Kao, P. F., Banigan, M. G., Vanderburg, C. R., McKee, A. C., Polgar, P. R., Seshadri, S., & Delalle, I. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825d06b7 · Cited by 31
Tucholka, A., Grau-Rivera, O., Falcon, C., Rami, L., Sánchez-Valle, R., Lladó, A., Gispert, J. D., Molinuevo, J. L., & Initiative, F. T. A. D. N. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170553 · Cited by 29
Veneziani, F., Panza, F., Solfrizzi, V., Capozzo, R., Barulli, M. R., Leo, A., Lozupone, M., Fontana, A., Arcuti, S., Copetti, M., et al. (2016) · International Psychogeriatrics · doi:10.1017/s1041610216000041 · Cited by 27
Biomarker-based signature of alzheimer's disease in pre-MCI individuals
Chipi, E., Salvadori, N., Farotti, L., & Parnetti, L. (2019) · Brain Sciences · doi:10.3390/brainsci9090213 · Cited by 27
Zhukovsky, P., Coughlan, G., Buckley, R., Grady, C., & Voineskos, A. N. (2023) · Human Brain Mapping · doi:10.1002/hbm.26148 · Cited by 26
Dumbbell Aptamer Sensor Based on Dual Biomarkers for Early Detection of Alzheimer’s Disease
Zhou, J., Sun, Y., Zhang, J., Luo, F., Ma, H., Guan, M., Feng, J., & Dong, X. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c21379 · Cited by 26
Präventionsstrategien gegen Demenz
Müller, P., Schmicker, M., & Müller, N. G. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1202-x · Cited by 25
Newton, P., the BIOCARD Research Team, Tchounguen, J., Pettigrew, C., Lim, C., Lin, Z., Lu, H., Moghekar, A., Albert, M., & Soldan, A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220846 · Cited by 23
Miller, S. R., Luxem, K., Lauderdale, K., Nambiar, P., Honma, P. S., Ly, K. K., Bangera, S., Bullock, M., Shin, J., Kaliss, N., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114870 · Cited by 24
“10,11 12-14 Thus, these behavioral changes may be the earliest symptoms of preclinical stages of AD.”
Preventing cognitive decline in preclinical Alzheimer's disease
Riedel, W. J. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.10.002 · Cited by 22
Digital screening for cognitive impairment - a proof of concept study
Bloniecki, V., Hagman, G., Ryden, M., & Kivipelto, M. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.2 · Cited by 21
Gao, L., Chen, J., Gu, L., Shu, H., Wang, Z., Liu, D., Yan, Y., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00256 · Cited by 21
Alzheimer’s Disease: Dawn of a New Era?
Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21
“Therefore, literature suggest that AD should be divided into three phases: (a) Preclinical AD: Very early signs and symptoms: patient has more memory problems than normal, but symptoms are not severe, and their ability to participate in normal daily activity is not impaired (39); (b) Mild cognitive impairment (MCI): m…”
BackgroundMultistate models and lifetime risk estimation: application to Alzheimer's disease
Brookmeyer, R., & Abdalla, N. (2019) · Statistics in Medicine · doi:10.1002/sim.8056 · Cited by 20
MUKHTAR, G., & FARHAN, S. (2020) · Advances in Electrical and Computer Engineering · doi:10.4316/aece.2020.02013 · Cited by 19
Lin, C., Ly, M., Karim, H. T., Wei, W., Snitz, B. E., Klunk, W. E., & Aizenstein, H. J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0573-1 · Cited by 19
Artificial intelligence detection of cognitive impairment in older adults during walking
Obuchi, S. P., Kojima, M., Suzuki, H., Garbalosa, J. C., Imamura, K., Ihara, K., Hirano, H., Sasai, H., Fujiwara, Y., & Kawai, H. (2024) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.70012 · Cited by 18
Devanarayan, V., Charil, A., Horie, K., Doherty, T., Llano, D. A., Andreozzi, E., Sachdev, P., Ye, Y., Murali, L. K., Zhou, J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14411 · Cited by 19
Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model
Reinitz, F., Chen, E. Y., Nicolis di Robilant, B., Chuluun, B., Antony, J., Jones, R. C., Gubbi, N., Lee, K., Ho, W. H. D., Kolluru, S. S., et al. (2022) · eLife · doi:10.7554/elife.66037 · Cited by 18
Jiang, L., Lin, H., Initiative, A. D. N., & Chen, Y. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134824 · Cited by 17
Subjective cognitive impairment: Fickle but fateful
Knopman, D. S. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1bd1 · Cited by 17
Metabolites Associated with Early Cognitive Changes Implicated in Alzheimer’s Disease
Darst, B. F., Huo, Z., Jonaitis, E. M., Koscik, R. L., Clark, L. R., Lu, Q., Kremen, W. S., Franz, C. E., Rana, B., Lyons, M. J., et al. (2021) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200176 · Cited by 16
Zehirlioglu, L., Erunal, M., Akyol, M. A., Mert, H., Hatipoglu, N. S., & Kucukguclu, O. (2019) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0000000000000433 · Cited by 13
Detecting the effect of genetic diversity on brain composition in an Alzheimer’s disease mouse model
Gurdon, B., Yates, S. C., Csucs, G., Groeneboom, N. E., Hadad, N., Telpoukhovskaia, M., Ouellette, A., Ouellette, T., O’Connell, K. M. S., Singh, S., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06242-1 · Cited by 15
Chen, P., Hsu, H., Chao, Y., Nouchi, R., Wang, P., & Cheng, C. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13691 · Cited by 14
Theoretical impact of the AT(N) framework on dementia using a community autopsy sample
Burke, B. T., Latimer, C., Keene, C. D., Sonnen, J. A., McCormick, W., Bowen, J. D., McCurry, S. M., Larson, E. B., & Crane, P. K. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12348 · Cited by 13
Whittaker, H. T., Zhu, S., Di Curzio, D. L., Buist, R., Li, X.-M., Noy, S., Wiseman, F. K., Thiessen, J. D., & Martin, M. (2018) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2018.03.010 · Cited by 12
Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer’s Disease
Gomar, J. J., Conejero-Goldberg, C., Davies, P., Goldberg, T. E., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150937 · Cited by 13
TM2D genes regulate Notch signaling and neuronal function in Drosophila
Salazar, J. L., Yang, S.-A., Lin, Y. Q., Li-Kroeger, D., Marcogliese, P. C., Deal, S. L., Neely, G. G., & Yamamoto, S. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009962 · Cited by 13
Harrison, T. M., & Bookheimer, S. Y. (2016) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2015.09.003 · Cited by 12
Locke, D. E. C., Chandler Greenaway, M., Duncan, N., Fields, J. A., Cuc, A. V., Hoffman Snyder, C., Hanna, S., Lunde, A., & Smith, G. E. (2014) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.27 · Cited by 11
Shimizu, Y., Sawada, N., Ihira, H., Abe, S. K., Inoue, M., Yasuda, N., Yamagishi, K., Iwasaki, M., & Tsugane, S. (2023) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5896 · Cited by 9
Fongsaran, C., Jirakanwisal, K., Peng, B.-H., Fracassi, A., Taglialatela, G., Dineley, K. T., Paessler, S., & Cisneros, I. E. (2024) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2024.100780 · Cited by 9
Generating MRI ‐Derived CSF Proxy‐Markers to Predict and Visualize Alzheimer's Disease Progression
Abrol, A., Calhoun, V. D., & Initiative, T. A. D. N. (2025) · Human Brain Mapping · doi:10.1002/hbm.70391 · Cited by 3
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
